02Jul 2023
Testosterone-replacement therapy does not increase cardiac events in men with hypogonadism

Testosterone-replacement therapy does not increase cardiac events in men with hypogonadism

A groundbreaking study, the TRAVERSE trial, reveals that testosterone-replacement therapy does not pose a heightened risk of heart-related issues in men with hypogonadism and a high risk of cardiovascular disease. This crucial finding dismisses previous concerns about the therapy's potential adverse cardiac events, which were primarily based on limited trials and observational studies. The results of this extensive study provide reassurance regarding the cardiovascular safety of testosterone-replacement therapy, paving the way for improved treatment options for individuals with hypogonadism.

  • #cardiology

Like

Save

Share